Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis
Open Access
- 4 April 2024
- journal article
- research article
- Published by Springer Nature in Systematic Reviews
- Vol. 13 (1) , 1-31
Abstract
Background: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients. Methods: A systematic search was conducted in MEDLINE (PubMed), Science Direct, Scopus, and Cochrane Library databases. Studies were selected if they included Asian breast cancer patients treated with neoadjuvant chemotherapy and contained data for qualitative or quantitative analyses. The quality of the included studies was assessed using the Newcastle Ottawa Scale. Following the random effects model, pooled odds ratios or hazard ratios with 95% confidence intervals for pCR were analysed using Review Manager Software. Heterogeneity between studies was assessed using Cochran’s Q-test and I2 test statistics. Results: In total, 19,708 Asian breast cancer patients were pooled from 101 studies. In the neoadjuvant setting, taxane-anthracycline (TA) chemotherapy showed better pCR outcomes in triple-negative breast cancer (TNBC) (ppppPIK3CA were significantly associated with better pCR outcomes when treated with TA in the neoadjuvant setting (p=0.001). Conclusions: In the neoadjuvant setting, molecular subtypes (HER2E and TNBC), biomarkers (ER, PR, HER2, HR, Ki-67, nm23-H1, CK5/6, and Tau), and gene (PIK3CA) are associated with increased pCR rates in Asian breast cancer patients. Hence, they could be further explored for their possible role in first-line treatment response, which can be utilised to treat breast cancer more efficiently in the Asian population. However, it needs to be further validated with additional powered studies. Systematic review registration: PROSPERO CRD42021246295.Keywords
All Related Versions
This publication has 151 references indexed in Scilit:
- Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2-Positive Breast Cancer: A Phase II Clinical TrialThe Oncologist, 2020
- Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in AsiaJAMA Oncology, 2020
- Insights Into Breast Cancer in the East vs the WestJAMA Oncology, 2019
- Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trialCancer, 2019
- RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapyJournal of Cellular Biochemistry, 2018
- Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safetyInternational Journal of Clinical Oncology, 2017
- Outcome after neoadjuvant chemotherapy in Asian breast cancer patientsCancer Medicine, 2016
- TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide‐based neoadjuvant chemotherapy in operable primary breast cancerInternational Journal of Cancer, 2015
- Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancerJournal of Cancer Research and Clinical Oncology, 2011
- Is Breast Cancer the Same Disease in Asian and Western Countries?World Journal of Surgery, 2010